Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H30N6OS |
Molecular Weight | 426.578 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=NN(C(=C1)N2CCN(CC2)[C@@H]3CN[C@@H](C3)C(=O)N4CCSC4)C5=CC=CC=C5
InChI
InChIKey=WGRQANOPCQRCME-PMACEKPBSA-N
InChI=1S/C22H30N6OS/c1-17-13-21(28(24-17)18-5-3-2-4-6-18)26-9-7-25(8-10-26)19-14-20(23-15-19)22(29)27-11-12-30-16-27/h2-6,13,19-20,23H,7-12,14-16H2,1H3/t19-,20-/m0/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/23671395Curator's Comment: description was created based on several sources, including https://www.pmda.go.jp/files/000153594.pdf
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23671395
Curator's Comment: description was created based on several sources, including https://www.pmda.go.jp/files/000153594.pdf
Teneligliptin is a DPP IV inhibitor which was developed by Mitsubishi Tanabe Pharma and now is used for the treatment of type 2 diabetes mellitus in Asia under the name Tenelia.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL284 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23671395 |
0.889 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | TENELIA Approved UseType 2 diabetes mellitus. Launch Date1.33548474E12 |
PubMed
Title | Date | PubMed |
---|---|---|
Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. | 2013 Sep |
|
Teneligliptin as an initial therapy for newly diagnosed, drug naive subjects with type 2 diabetes. | 2014 Aug |
|
Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor, Improves Early-Phase Insulin Secretion in Drug-Naïve Patients with Type 2 Diabetes. | 2015 Sep |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.pmda.go.jp/files/000153594.pdf
The usual adult dosage is 20 mg of teneligliptin administered orally once daily. If efficacy is insufficient, the dose may be increased up to 40 mg once daily while closely monitoring the clinical course.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27530507
Human umbilical vein endothelial cells were cultured under normal (5 mmol/L) or high glucose level (25 mmol/L) during 21 days, or at high glucose during 14 days followed by 7 days at normal glucose, to reproduce the high-metabolic memory state. At this time, different concentrations of teneligliptin (0.1, 1.0 and 3.0 umol/L) were added to cells. Teneligliptin was shown to protect human umbilical vein endothelial cells from oxidative stress.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C98086
Created by
admin on Fri Dec 15 17:17:10 UTC 2023 , Edited by admin on Fri Dec 15 17:17:10 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB11950
Created by
admin on Fri Dec 15 17:17:10 UTC 2023 , Edited by admin on Fri Dec 15 17:17:10 UTC 2023
|
PRIMARY | |||
|
8994
Created by
admin on Fri Dec 15 17:17:10 UTC 2023 , Edited by admin on Fri Dec 15 17:17:10 UTC 2023
|
PRIMARY | |||
|
m11707
Created by
admin on Fri Dec 15 17:17:10 UTC 2023 , Edited by admin on Fri Dec 15 17:17:10 UTC 2023
|
PRIMARY | |||
|
4895
Created by
admin on Fri Dec 15 17:17:10 UTC 2023 , Edited by admin on Fri Dec 15 17:17:10 UTC 2023
|
PRIMARY | |||
|
760937-92-6
Created by
admin on Fri Dec 15 17:17:10 UTC 2023 , Edited by admin on Fri Dec 15 17:17:10 UTC 2023
|
PRIMARY | |||
|
11949652
Created by
admin on Fri Dec 15 17:17:10 UTC 2023 , Edited by admin on Fri Dec 15 17:17:10 UTC 2023
|
PRIMARY | |||
|
100000138879
Created by
admin on Fri Dec 15 17:17:10 UTC 2023 , Edited by admin on Fri Dec 15 17:17:10 UTC 2023
|
PRIMARY | |||
|
C87623
Created by
admin on Fri Dec 15 17:17:10 UTC 2023 , Edited by admin on Fri Dec 15 17:17:10 UTC 2023
|
PRIMARY | |||
|
Teneligliptin
Created by
admin on Fri Dec 15 17:17:10 UTC 2023 , Edited by admin on Fri Dec 15 17:17:10 UTC 2023
|
PRIMARY | |||
|
28ZHI4CF9C
Created by
admin on Fri Dec 15 17:17:10 UTC 2023 , Edited by admin on Fri Dec 15 17:17:10 UTC 2023
|
PRIMARY | |||
|
DTXSID30997419
Created by
admin on Fri Dec 15 17:17:10 UTC 2023 , Edited by admin on Fri Dec 15 17:17:10 UTC 2023
|
PRIMARY | |||
|
SUB79262
Created by
admin on Fri Dec 15 17:17:10 UTC 2023 , Edited by admin on Fri Dec 15 17:17:10 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)